Risk factors
Cabaletta Bio (CABA) risk factors
Item 1A of every Cabaletta Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors110 risks14 new6 dropped23 reworded
Cabaletta Bio added risks regarding single-arm registrational trials using external controls and recent equity financings totaling millions of shares. The company faces increased FDA scrutiny on trial design and potential dilution from the 2025 Offering.
Filed Mar 23, 2026 - FY2024 10-K risk factors102 risks
Cabaletta Bio is an early-stage clinical biotechnology company developing engineered T cell therapies for autoimmune diseases.
Filed Mar 31, 2025